CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

CYFENDUS

RegulatoryCYFENDUSNeutral
AI Analysis

Summary

CYFENDUS is a post-exposure prophylactic vaccine for suspected or confirmed Bacillus anthracis exposure in adults aged 18-65, to be used with antibacterial regimens. The article provides indication details without specifying approval status or regulatory decision date.

Importance:3/10
Sentiment:
0.00
vaccineanthraxpost-exposure prophylaxisFDA approval
Related Companies

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on August 17, 2026 3:08 PM

Read Original